论文部分内容阅读
冠状动脉粥样硬化斑块或血栓形成造成狭窄或阻塞,使心肌细胞发生缺血性损伤。及时地重建心脏血供,对于减轻心脏缺血性损伤,保持心脏功能具有重要意义。但缺血长达一定时间后恢复血液供血,反而可以加重心肌的损伤,称为心肌缺血再灌注损伤(MyocardialIschemia-ReperfusionInjuryMIRI),这主要表现为细胞内钙超载,细胞肿胀,心肌细胞超微结构的急剧溃变,心肌顿抑、细胞酶的释放,心律失常和心功能的损害。除经典的冠脉搭桥术外,20世纪80年代以来,随着急性心梗溶栓术、经皮腔内冠状动脉成形术(PTCA)的开展应用,心肌缺血再灌注损伤已受到广大基础和临床工作者的重视,探索防治心肌缺血再灌注损伤的药物
Coronary atherosclerotic plaque or thrombosis caused by stenosis or obstruction, so that myocardial cells ischemic injury. Timely reconstruction of cardiac blood supply, for the mitigation of cardiac ischemic injury, maintain cardiac function is of great significance. However, ischemia for a certain period of time to restore blood supply, but can increase myocardial damage, known as myocardial ischemia-reperfusion injury (MyocardialIschemia-ReperfusionInjuryMIRI), which are mainly manifested as intracellular calcium overload, cell swelling, myocardial cell ultrastructure Rapid breakdown, myocardial stunning, release of cellular enzymes, arrhythmia, and impaired cardiac function. In addition to the classic coronary artery bypass grafting, since the 1980s, with the application of acute myocardial infarction and percutaneous transluminal coronary angioplasty (PTCA), myocardial ischemia-reperfusion injury has been extensively based and Clinicians pay attention to explore the prevention and treatment of myocardial ischemia-reperfusion injury drugs